Celularity raises FY 2024 net sales guidance to $54-60M; October sales hit record $8.3-8.9M

Celularity Inc

Raises full-year 2024 expected net sales guidance to $54M-$60M from $50M-$56M, citing strong advanced biomaterial sales.
Expected net sales through October 31, 2024: $44.4M ($40.2M advanced biomaterials, $4.2M biobanking); includes ~$9M from new Rebound product.
October 2024 expected net sales of $8.3M-$8.9M marks highest-ever single-month figure.
Filed Q2 2024 Form 10-Q on Nov 6, resolving Nasdaq non-compliance notice from Oct 16, 2024.
Advanced biomaterial product sales for first half 2024 exceeded $24M, surpassing full-year 2023 total.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.